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CLINICAL STUDIES ON TSAA－29！ IN THE TREATMENT
         OF BENIGN PROSTATIC HYPERTROPHY
                   （THE SECOND REPORT）
   … A TRANSRECTAL ULTRASONOTOMOGRAPHIC STUPY OF
      REDUCTION EFFECT ON THE PROSTATIC WEIGHT ・一・
Yoshikatsu SAwAMuRA， ，Norihiko MuRAKAMi， Kiyoshi FuKAzAwA，
                Koichi NAKAyAMA and Ko ANDo
Fr・m the・0吻吻認（ガ伽」・9」・， Sch・・♂ヴ餓麗’ze， Tah・伽口吻，． T・Lv・，ノ4Pan
                      rD惚嬬PrOf．・κ． And・ノ
    1） Twenty eases with advanced benign prostatic hypertrophy indicated for surgical treatments
were administered intramuscularly with 400 mgfweek of TSAA－291 for 13 weeks：
   Among’them， 15 cases were closely followed up after the treatment． During the follgw－up， their
prostatic weights did not change much on measure皿ent using transrectal ultrasonotomography and
rio rebound effect was recognized． 12 gf 15 ’cases have been kept under satisfactory conditions with
symptomatic treatment Qnly’fqr at longest 24 months （average 14 months） after TSAA－291 treqtment．
   OnlY．3 cases needed’ surgical t．reatments up to now among the above 2e cases．
   The i2 cafies will be further ggllowed’up．， and on relapse’TSAA－291 is to．be administered again．
’ 2） TSt“A－291 was．adrpiniste．red intralnuscularlY 2eO mg （1 vial）Xweek’to other 12 cases． Relief
of subjectiVe symptoinsi was’ obtained in 9 cases 〈750／．）， and a’decrease 6f necturnal frequency in 8
（670／，）． ln 5 （420／．）， a reductive change．was noticed on the prosta’tic weight． These respdnses were
as good as those to 400 mg （2’vials）fweek， though a difference in stage of the disease might be between
the cases treated with 400 mg／week and those treated with 200 mgfweek．
   The variety and frequency of side effects were significantly less in the 200 mg／week group than
those in the 400 mg／week one．
   The clinical improvement ．mentioned above indicates that a satisfactory therapeutic effect will
be obtained in proper cases with 200 mg． （1 vial）／week ・of． TSAA－291． It is tli．erefore a question of
further studieS that only the cases who fail to respond enough to the 200 mg／week treatment， are suc－
cessively treated with 400 mg／week of TSAA－291．
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No 4 2－3 2一一3
Dysuria 3 3 4
No 5－62 2
No R 4－5 3
No 1 ］ l
Pollaki一 2 1－2 3－4uria
No     バ1   2
Pollaki一一 Rrt4一一5 2－3
u酉a
Sense of 7 2 2．re’tention
No 3－42 2
No 2 0 O
Dysuria 3 4 4
No R＊2 1
No ltk 2 2
















          9 months after
38．0〈77．6＞ 40．3（82．2）
22．3（gs．7）iQiTg？8：f，3fter ［，
          3 months after
27．5（90．2） 27．0（88．5）
         18 months after
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          3 months after
30．0（92．3） 29．4（90．5｝
           3 months after
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          19 months after
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           9 months after
25．8（85。1｝ 26．8く88。4）














 9 months after 13 months after
33．8（89．4） 36．5（96．6）






nf Retention of urine， Btc：Before adrnlnistration，
Ratiott（％）：met h t ft d t t x l oo









































Before Oktreatment 3 6 （ months ）9
      （k ： End of treatment ）
Fig． 1． Change of prostqtic weight after TSAA－291’ treatment





























Table 2．The 12 cases treated with 200 mg（1 via1）of TSAA－291 a week for 13 weeks，
dose SLibJect’ive sympt：nms NQcturnal frequmqy Prostaze weightSjde effectR marks ＿一Case Name Age W ekTy
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   ” Effecti ve 2－3
   ” Eft’ecti ve 4
   ” Effective 5－6
   ” Effect’ive 3－4
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Sl ght fever
Residual urine after
treatment： less than 30 ml．
Discontinued after administration
of ooO mg x 7（TSAA－291） on accoun’t
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    Before After    treatment treatment
Fig． 2． Change of prostatic weight during
    TSAA－291 treatment （200 mg’x 13
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Fig． 3． Ultrasonotomograms of the prostate before and after
    TSAA－291 treatment （200 mg y 13weeks） in case No． 3




































 （第ll幸艮）． 日超医論文集， 23：71， 1973．
3）渡辺 決：経直腸的超音波断層法の開発と応用．
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